CERS
Cerus Corp
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Cerus has 5 disclosed suppliers and 6 disclosed customers in SEC filings.
Last report2 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
SentenceWith the exception of certain components, we rely solely on Fresenius Kabi AG, or Fresenius, for the manufacture of disposable kits for the platelet and plasma systems.
CERS 10-Kaccession 0001193125-26-085678
SentenceFresenius Kabi AG, Fenwal France SAS, and Fenwal International, Inc., or collectively, Fresenius, manufactures and supplies the platelet and plasma systems to us under our Second Amended and Restated Supply and Manufacturing Agreement, or the 2022 Agreement, until December 31, 2031.
CERS 10-Kaccession 0001193125-26-085678
SentenceWe operate with an amended manufacturing and supply agreement with Piramal, formerly, Ash Stevens, Inc., for the synthesis of amotosalen, the inactivation compound used in our platelet and plasma systems.
CERS 10-Kaccession 0001193125-26-085678
SentenceSecond Amended and Restated Supply and Manufacturing Agreement, dated December 9, 2024, by and between Cerus Corporation and Porex Corporation.
CERS 10-Kaccession 0001193125-26-085678
SentenceWe also have an amended and restated supply agreement with Purolite LLC, formerly Purolite Corporation, or Purolite, for the supply of raw materials used to make the compound adsorption devices.
CERS 10-Kaccession 0001193125-26-085678
SentenceThe American Red Cross represents the largest single portion of the blood collection market in the U.S. and is one of our key customers.
CERS 10-Kaccession 0001193125-26-085678
Sentence
In June 2016, we entered into an agreement with BARDA, or the 2016 BARDA Agreement, to support our development and implementation of pathogen reduction technology for platelet, plasma, and red blood cells, including access to funding that could potentially support various activities, including conducting studies necessary to support a potential premarket approval application submission to the FDA for the red blood cell system, and accelerating commercial scale up activities to facilitate potential adoption of the red blood cell system by U.S. blood centers.
CERS 10-Kaccession 0001193125-26-085678
SentenceWhile we have entered into agreements with Établissement Français du Sang, or EFS, to supply illuminators, platelet and plasma disposable kits, maintenance services for illuminators and ancillary pooling sets to EFS, we cannot provide any assurance that the national deployment of the platelet system in France will be sustainable or that we will be able to secure any contracts subsequent to our existing contract extensions with EFS.
CERS 10-Kaccession 0001193125-26-085678
SentenceIn September 2020, we entered into a five-year agreement with the FDA for the development of next-generation compounds to optimize pathogen reduction treatment of whole blood to reduce the risk of transfusion-transmitted infections.
CERS 10-Kaccession 0001193125-26-085678
SentenceIn February 2021, we entered into an Equity Joint Venture Contract with Shandong Zhongbaokang Medical Implements Co., Ltd., or ZBK, to establish Cerus Zhongbaokang (Shandong) Biomedical Co., LTD., which we refer to as the JV, for the purpose of developing, obtaining regulatory approval for, and eventual manufacturing and commercialization of the INTERCEPT blood transfusion for platelets and red blood cells in the People's Republic of China.
CERS 10-Kaccession 0001193125-26-085678
SentenceIn September 2022, we entered into an agreement with the U.S. Department of Defense, or DoD, for the development of pathogen reduced, lyophilized cryoprecipitate ("Lyo-Cryo") to treat bleeding due to trauma.
CERS 10-Kaccession 0001193125-26-085678
−25.61%
vs ±19.7% implied · ×1.30
shaded = implied · ▲▼ = realized
Cerus Corp
2.28
Largest filed tie
—
Expected move
Inputs8Q avg ±14.6%·×2.00·rich
straddle ±30.8%
spot 2.28exp Nov 20ATM strike 2ATM straddle 0.83IV 196%